AUCKLAND: AFT Pharmaceuticals notes the US Food and Drug Administration (FDA) has approved a topical treatment indicated for facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC) developed by Japan’s Nobelpharma . The active ingredient in Nobelpharma’s medicine is rapamycin, which AFT and its development partner, the US-based Timber Pharmaceuticals, are also developing as a…